Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diphenhydramine topicals warning against use on "large areas" of body endorsed by NDMA.

This article was originally published in The Tan Sheet

Executive Summary

DIPHENHYDRAMINE WARNING ON USE OVER "LARGE AREAS" OF BODY ENDORSED BY NDMA for topical OTC products in Nov. 25 comments to FDA. The Nonprescription Drug Manufacturers Association also endorses a label warning against use with other products containing diphenhydramine. The letter responds to FDA's advance notice of proposed rulemaking for OTC diphenhydramine-containing products, published Aug. 29, which would require topical diphenhydramine products to carry warnings against use in cases of chicken pox, poison ivy or sunburn, on large areas of the body, on blistered or oozing skin, more often than directed or with any other diphenhydramine-containing drug, including those taken orally ("The Tan Sheet" Sept. 1, p. 4).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel